IGF-1 DES
Truncated IGF-1 variant lacking the first three amino acids. Higher potency than IGF-1 LR3 at injection site with a much shorter half-life; used for localised muscle anabolism.
0 anonymous reports
Also known as:
des igf-1des 1-3 igf-1truncated igf
browse topics:
No reports found.
Community Q&A
- What's the difference between IGF-1 DES and IGF-1 LR3?
- Community accounts consistently describe IGF-1 DES as the local-action variant and IGF-1 LR3 as the systemic variant. DES lacks the binding domain that attaches to serum binding proteins, so it stays near the injection site and acts with very high local potency for 20–30 minutes. LR3 circulates systemically for up to 30 hours. Accounts that want to target a specific muscle group describe DES as more suitable; accounts seeking whole-body anabolic effects describe LR3.
- How is IGF-1 DES injected?
- Community accounts describe intramuscular injection directly into the target muscle within 30 minutes of training — the intent being to maximise local satellite cell activation in the trained muscle. The short activity window is described as requiring precise timing. Post-workout injection into a lagging muscle group is the dominant protocol in bodybuilding-focused accounts. Systemic hypoglycaemia risk appears at higher doses — accounts consistently warn about testing sensitivity before significant dose increases.